Get the Stockscreener App
0.9381
1.50%
-0.0143
After Hours:
.96
0.0219
+2.33%
Senti Biosciences Inc stock is traded at $0.9381, with a volume of 65,026.
It is down -1.50% in the last 24 hours and up +14.10% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$0.9524
Open:
$0.9524
24h Volume:
65,026
Relative Volume:
0.04
Market Cap:
$24.66M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.0604
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
-4.37%
1M Performance:
+14.10%
6M Performance:
-32.51%
1Y Performance:
-70.41%
1-Day Range:
$0.9161
$0.9799
1-Week Range:
$0.8801
$0.986
52-Week Range:
$0.797
$5.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
0.9381 | 25.04M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference - Bitget
Miami healthcare conference talk from Senti Bio CEO will be webcast live - Stock Titan
SNTI PE Ratio & Valuation, Is SNTI Overvalued - Intellectia AI
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
SNTI Should I Buy - Intellectia AI
Senti Biosciences (NASDAQ:SNTI) Shares Up 1.6% – Should You Buy? - Defense World
Senti Bio Participates in Cell & Gene Live Event on Innovative Therapies - Intellectia AI
Senti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care Conference - Quiver Quantitative
Senti Bio CEO to highlight gene circuit pipeline at TD Cowen conference - Stock Titan
Senti Biosciences: A Waiting Game for Investors () - aktiencheck.de
SNTI Stock Price, Forecast & Analysis | SENTI BIOSCIENCES INC (NASDAQ:SNTI) - ChartMill
Can Senti Biosciences Inc. sustain its profitability2025 Big Picture & Weekly High Return Stock Opportunities - mfd.ru
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development - The Manila Times
How a cell therapy event spotlighted Senti Bio’s ‘logic-gated’ treatments - Stock Titan
Senti Biosciences reports promising phase 1 trial results - MSN
Will Senti Biosciences Inc. be affected by tariffsJuly 2025 Sector Moves & Verified Momentum Watchlists - mfd.ru
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Insider Trends: What are the analyst revisions for Senti Biosciences IncIs ICON stock a good investment in YEARJuly 2025 Spike Watch & Accurate Trade Setup Notifications - baoquankhu1.vn
Published on: 2026-02-16 00:06:47 - mfd.ru
Can Senti Biosciences Inc. deliver alphaTrade Signal Summary & Daily Entry Point Trade Alerts - mfd.ru
Senti Biosciences completes enrollment in Phase 1 clinical trial of Senti-202 - marketscreener.com
Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202 - TradingView
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) - The Manila Times
Leukemia cell therapy SENTI-202 heads for FDA talks after early remissions - Stock Titan
Does Senti Biosciences Inc. have a sustainable dividendShare Buyback & Smart Allocation Stock Tips - mfd.ru
Retail Surge: Is FONR benefiting from interest rate changesIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Gains Recap: Does Senti Biosciences Inc have a sustainable dividendMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Aug Mood: Should I trade or invest in Senti Biosciences IncInsider Selling & AI Forecast Swing Trade Picks - baoquankhu1.vn
Growth Value: What are the analyst revisions for Senti Biosciences IncIs ICON stock a good investment in YEAR2025 Top Decliners & Accurate Technical Buy Alerts - baoquankhu1.vn
Aug Movers: Does Senti Biosciences Inc have a sustainable dividend2025 Winners & Losers & Verified Momentum Stock Alerts - baoquankhu1.vn
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 - The Manila Times
Inside Senti Bio’s 8-minute gene circuit pitch at Taipei’s 2026 healthcare conference - Stock Titan
Insider Buy: Is Senti Biosciences Inc stock good for income investorsJuly 2025 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn
US Market Recap: Will EQT Corporation stock go up in YEARPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Can Senti Biosciences Inc sustain its profitability2025 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Market Rankings: Is Senti Biosciences Inc benefiting from innovation trendsJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Block Trades: Is Senti Biosciences Inc benefiting from innovation trendsInflation Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - marketscreener.com
Senti Biosciences, Inc. Highlights FDA RMAT Designation for SENTI-202 in Virtual Investor CEO Connect Segment - Quiver Quantitative
Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation - The Manila Times
FDA RMAT status and early leukemia data put Senti Bio therapy in focus - Stock Titan
Published on: 2026-01-14 09:14:03 - Bộ Nội Vụ
Breakouts Watch: Should I hold or sell Senti Biosciences Inc stock in 2025 - Bộ Nội Vụ
Senti Biosciences, Inc. (NASDAQ:SNTI) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference - The Manila Times
Trading Action: Why Senti Biosciences Inc. stock is a value investor pickJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - ulpravda.ru
Quarterly Recap: Can Senti Biosciences Inc. stock beat market expectations this quarterPortfolio Value Summary & Smart Money Movement Tracker - ulpravda.ru
Will Senti Biosciences Inc. stock outperform value stocksRisk Management & AI Forecasted Stock Moves - Улправда
Why Senti Biosciences Inc. stock is a value investor pick2025 Sector Review & Free Daily Entry Point Trade Alerts - Улправда
Why Senti Biosciences Inc. stock remains on buy listsM&A Rumor & Growth Focused Investment Plans - Улправда
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):